Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-13
2006-06-13
Turner, Sharon (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07060676
ABSTRACT:
The invention relates toT. cruzitrans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and/or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and/or neurotrophic peptide. TS, IL-6 secretion-inducing variants and/or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and/or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and/or active peptides and a physiologically acceptable carrier.
REFERENCES:
patent: 5980885 (1999-11-01), Weiss et al.
patent: 6033660 (2000-03-01), Mather et al.
patent: 6037320 (2000-03-01), Rosenthal
patent: 6054294 (2000-04-01), Chang
patent: 6093802 (2000-07-01), Lin et al.
patent: 6124328 (2000-09-01), Armistead
patent: 6143714 (2000-11-01), Wong et al.
patent: 6167888 (2001-01-01), Tuszynski et al.
patent: 6172086 (2001-01-01), Zelle et al.
patent: 6174862 (2001-01-01), Brenneman
patent: 6177402 (2001-01-01), Bartlett et al.
patent: 6214796 (2001-04-01), Finklestein
Stratagene, Product Info—pBlueScript® II Phagemid Vector obtained at “www.stratagene.com/products/displayProduct.aspx?pid=267”.
ATCC Accession No. 87047 product info and map obtained at “www.atcc.org/SearchCatalogs/directdetail.cfm?collection=mb-vector&atccNum=87047”.
Genebank Accession No. AJ002174, “Trypanosoma Cruzi Trans-Sialidase Gene, Clone 19y, 5′-region,” (1999) [online], [retrieved on Apr. 18, 2001]. Retrieved from the internet: <URL:http://www.ncbi.nlm.nih.gov>.
Genebank Accession No. M61732, “T. Cruzi Neuraminadose (TCNA) Gene, Complete cds,” (1994) [online], [retrieved on Apr. 18, 2001]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov>.
“Table of Contents,”J. Exp. Med. 190(12) (1999) [online], [retrieved on Dec. 13, 1999]. Retrieved from the Internet: <URL:http://intl.jem.org/future/190.12.shtml>.
Chuenkova, M.V. and Pereira, M.A., “A Trypanosomal Protein Synergizes with the Cytokines Ciliary Neurotrophic Factor and Leukemia Inhibitory Factor to Prevent Apoptosis of Neuronal Cells,”Molecular Biology of the Cell, 11:1487-1498 (2000).
Prasad, K.N., “Differentiation of Neuroblastoma Cells: A Useful Model for Neurobiology and Cancer,”Biol. Rev., 66:431-451 (1991).
Schenkman, S. et al., “Structural and Functional Properties of Trypanosoma Trans-Sialidase,”Annu. Rev. Microbiol., 48:499-523 (1994).
Pereira, M.E. et al., “The Trypanosoma Cruzi Neuraminidase Contains Sequences Similar to Bacterial Neuraminidases, YWTD Repeats of the Low Density Lipoprotein Receptor, and Type III Modules of Fibronectin,”J. Exp. Med., 174(1):179-191 (1991).
Saavedra, E. et al., “The Trypanosoma Cruzi Trans-Sialidase, Through Its COOH-Terminal Tandem Repeat, Upregulates Interleukin 6 Secretion in Normal Human Intestinal Microvascular Endothelial Cells and Peripheral Blood Mononuclear Cells,”J. Exp. Med., 190(12):1825-1836 (1999).
Chuenkova, M. et al., “trans-Sialidaseof Trypanosoma cruzi: Location of Galactose-Binding Site(s),” Biochemical and Biophysical Research Communications, 262:549-556 (1999), Aug.
Chuenkova Marina
Pereira Miercio A.
Hamilton Brook Smith & Reynolds P.C.
Trustees of Tufts College
Turner Sharon
LandOfFree
T. cruzi -derived neurotrophic agents and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T. cruzi -derived neurotrophic agents and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T. cruzi -derived neurotrophic agents and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3673694